compani
rx trend track verzenio data approach
messag post-wclc data present updat
model reflect revis estim owe primarili assum
expans ret mutat market expect verzenio overal
surviv result monarch studi esmo game changer
help drug compet vs ibranc breast cancer market
make chang model review iqvia trend
suggest sale line slightli forecast maintain neutral
neutral potenti data regulatori catalyst expect
major stock-mov event year end balanc expect lli near-term
stock perform overshadow primarili polit legisl nois
appear laser focus insulin price well wide anticip approv price
launch novo oral semaglutid look much busier although
compani meaning clinic catalyst like emerg late
tirzepatid result diabet obes nash mix offset toler
vs impress efficaci product phase psoriasi crohns/ulc coliti
data mirikizumab data crohns/uc could first approv anti-
key hfpef result emperor-preserv studi jardianc
posit prospect broadli set final readout
verzenio adjuv breast cancer key result pfe ibranc
adjuv studi expect regulatori decis tanezumab chronic
osteoarthr extrem neg mechan key driver lli mid-
long-term prospect
result treatment patient ret fusions/mut nsclc
signific unmet medic need patient suffer ret fusions/mut
nsclc current approv target therapi although
small proport nsclc case lung cancer case per
present substanti global opportun importantli addit
previous treat patient result treatment-na patient impress
compet pralsetinib see note buy discuss
management highlight confid pralsetinib avapritinib competitor readout
schmidt analyst updat global sale estim
verzenio os data diseas esmo could set bar
metastat market investor focus adjuv reinvigor
growth esmo present final os result
monarch monarch studi magnitud posit surviv
benefit reveal balanc continu model lead
market ibranc primarili expect effort adjuv breast
cancer succeed howev ibranc fail deliv convinc treatment benefit
palla penelop studi door increas global uptak verzenio could
open drive increment market share gain particularli given investor
kol view efficaci variou inhibitor
novn extrem similar forecast verzenio global peak sale
iqvia trx trend base week data end suggest
line slightli estim trulic maintain trx market
share market share till date increasingli fast grow
competit type diabet market trulic compet novo
buy dkk ozemp expect competit novo oral
page analyst certif import disclosur
semgalutid launch key product like taltz emgal verzenio look
deliv in-lin slightli better-than-expect quarter insulin franchis
particularli humalog look continu pressur san-par admelog
page analyst certif import disclosur
valuat risk
fair valu rang reflect forecast sale profit
use larg pharmaceut compani discount rate termin
upsid risk includ trulic jardianc sale meaning estim
better expect oper leverag
downsid risk includ sustain price pressur diabet immunolog
potenti pricing/reb pressur emgal
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
